Prescribing of lipid regulating drugs and admissions for myocardial infarction in England

doi:10.1136/bmj.329.7467.645

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Azeem Majeed,
Paul Aylin,
Susan Williams,
Alex Bottle,
Brian Jarman

Despite declining death rates in recent decades, coronary heart disease remains one of the leading causes of death in England.^w1 Statins have been shown to reduce the risk of death and acute myocardial infarction in people who have coronary heart disease or are at high risk of developing it.^w2-w4 A key objective of the national service framework for coronary heart disease is to increase the uptake of statins in these two groups. We conducted an analysis of primary care prescribing of lipid regulating drugs and admission rates for acute myocardial infarction in the NHS for 1996-2002.